Watch the full version of the Emerging Markets: Shifting Environment of Clinical Trials in India webinar.
KEYNOTE Recent Updates to CT Regulations in India-A Summary
Sreedhar Tirunagari, Makro Care Clinical Research,
India, Medical Doctor, Clinical research Professional
He has been listed among 100 Most Inspiring People in the Life-Sciences Industry in the year 2012- „Pharma Voice Magazine“ ,Nominated for Clinical trial Innovation - 2nd Annual Partnerships in Clinical Trials Awards Ceremony, USA -2012, Finalist for „SCRIP AWARD -2012“ and Key Opinion Leader-Biowebspin.
The Central Drugs Standard Control Organization (CDSCO) in India has issued number of guidelines to strengthen clinical trial regulations in India after January
The aforesaid amendments to Schedule Y of the Rules came as a response to demands from the apex court, which were outraged by the lack of supervision and regulation of these clinical trials in India. Also as a response to the public interest litigation(s) filed by few NGOs working for the human rights of the vulnerable sections. The CDSCO and Ministry of Health and Welfare tightened the norms relating to the conduct of clinical trials and also the approval mechanism for such clinical trials.
Have you been wondering what the changes to CT regulations in India are, and unable to find a summary? This webinar will take you through helpful synthesis, including links to numerous resources and articles.
Central Drugs Standard Organization (CDSCO), India, Regulatory Affairs and Pharmacovigilance
Asia Area Medical Affairs Manager
Makro Care Clinical Research, India, Medical Doctor, Clinical research Professional
Join 3 TOP Experts on Clinical Trials in India on March 25
Despite India being a hub of clinical trials for drugs a huge wave of opposition to the practices for conducting clinical trials have raised. Questions are many and the future of the trials is being threatened. To shed light on this rather hazy situation, challenge our speakers and get the cutting-edge information.